277 related articles for article (PubMed ID: 17154657)
1. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Zehentner BK; Secrist H; Zhang X; Hayes DC; Ostenson R; Goodman G; Xu J; Kiviat M; Kiviat N; Persing DH; Houghton RL
Mol Diagn Ther; 2006; 10(6):397-403. PubMed ID: 17154657
[TBL] [Abstract][Full Text] [Related]
2. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
3. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM
J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056
[TBL] [Abstract][Full Text] [Related]
4. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
Ouyang B; Bracken B; Burke B; Chung E; Liang J; Ho SM
J Urol; 2009 Jun; 181(6):2508-13; discussion 2513-4. PubMed ID: 19371911
[TBL] [Abstract][Full Text] [Related]
5. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience.
Ji J; Chen X; Xu Y; Cao Z; Xu H; Kong C; Wang F; Sun Y
Cancer Control; 2019; 26(1):1073274819887697. PubMed ID: 31793344
[TBL] [Abstract][Full Text] [Related]
7. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
[TBL] [Abstract][Full Text] [Related]
8. Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer.
Koseoglu E; Tuncel A; Balci M; Kaya O; Aslan Y; Guzel O; Yilmaz FM; Atan A
Colomb Med (Cali); 2018 Jun; 49(2):164-168. PubMed ID: 30104809
[TBL] [Abstract][Full Text] [Related]
9. Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
Sroka WD; Adamowski M; Słupski P; Siódmiak J; Jarzemski P; Odrowąż-Sypniewska G; Marszałł MP
Int J Biol Markers; 2015 Nov; 30(4):e401-6. PubMed ID: 25982684
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Sreekumar A; Laxman B; Rhodes DR; Bhagavathula S; Harwood J; Giacherio D; Ghosh D; Sanda MG; Rubin MA; Chinnaiyan AM
J Natl Cancer Inst; 2004 Jun; 96(11):834-43. PubMed ID: 15173267
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Rogers CG; Yan G; Zha S; Gonzalgo ML; Isaacs WB; Luo J; De Marzo AM; Nelson WG; Pavlovich CP
J Urol; 2004 Oct; 172(4 Pt 1):1501-3. PubMed ID: 15371879
[TBL] [Abstract][Full Text] [Related]
12. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
[TBL] [Abstract][Full Text] [Related]
13. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ
Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799
[TBL] [Abstract][Full Text] [Related]
14. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.
Rubin MA; Zerkowski MP; Camp RL; Kuefer R; Hofer MD; Chinnaiyan AM; Rimm DL
Am J Pathol; 2004 Mar; 164(3):831-40. PubMed ID: 14982837
[TBL] [Abstract][Full Text] [Related]
15. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer.
Prior C; Guillen-Grima F; Robles JE; Rosell D; Fernandez-Montero JM; Agirre X; Catena R; Calvo A
World J Urol; 2010 Dec; 28(6):681-6. PubMed ID: 20632177
[TBL] [Abstract][Full Text] [Related]
16. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
17. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Gumulec J; Masarik M; Krizkova S; Hlavna M; Babula P; Hrabec R; Rovny A; Masarikova M; Sochor J; Adam V; Eckschlager T; Kizek R
Neoplasma; 2012; 59(2):191-201. PubMed ID: 22248277
[TBL] [Abstract][Full Text] [Related]
19. T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.
Eryilmaz IE; Kordan Y; Vuruskan BA; Kaygısız O; Tunca B; Cecener G
Gene; 2018 Mar; 645():69-75. PubMed ID: 29277318
[TBL] [Abstract][Full Text] [Related]
20. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Kumar-Sinha C; Shah RB; Laxman B; Tomlins SA; Harwood J; Schmitz W; Conzelmann E; Sanda MG; Wei JT; Rubin MA; Chinnaiyan AM
Am J Pathol; 2004 Mar; 164(3):787-93. PubMed ID: 14982833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
